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Amino acids, particularly glutamate, have been proposed to play an 
important role in the recovery of cardiac oxidative metabolism after 
ischemia. In this investigation, the metabolic and hemodynamic effects of 
glutamate infusion after coronary operations were studied. From 220 to 240 ml 
0.1 mol/L l-glutamic acid solution was infused in 10 patients during 1 hour 
starting 2 hours after operation. A control group of 10 patients received an 
infusion of 240 ml saline solution. During glutamate infusion, there were 
significant increases in the uptake of glutamate (from 0.7 +- 0.2/.tmol/min in 
the basal state to a peak of 5.7 -+ 1.2 pmol/min at 20 minutes) and lactate 
(from 4.9 -- 2.0 pmol/min in the basal state to 14.1 __ 4.4 /_tmol/min at 60 
minutes; p < 0.01), whereas the uptake and release of other substrates 
remained essentially unaffected. Arterial glutamate levels (in whole blood) 
increased from 103 -+ 10 btmol/L to 394 +- 20 pmol/L at 60 minutes. Thirty 
minutes after discontinuation of the glutamate infusion, arterial levels had 
decreased to 129 -- 17 pmol/L. The markedly improved utilization of lactate 
and the unchanged release of alanine together suggest that the oxidative 
metabolism of the heart was stimulated by glutamate. The metabolic hanges 
were associated with improved myocardial performance. Left ventricular 
stroke work index increased from 26.8 - 2.1 gin- beat -1. m -2 body surface 
area to 31.3 +_ 3.1 gin-beat -1. m -2 body surface area during glutamate 
infusion. Metabolic support with amino acids may provide a means to improve 
recovery of metabolic and hemodynamic function of the heart early after 
cardiac operations. (J Thorac Cardiovasc Surg 1996;112:1468-77) 
D efective oxidative metabolism of the heart after ischemia has been suggested as a major cause for 
reversible myocardial dysfunction early after cardiac 
operations.i, 2 Previous studies performed early af- 
ter coronary operations demonstrated a markedly 
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deranged myocardial metabolism, with no signifi- 
cant uptake of the normally dominant substrates, 
free fatty acids (FFAs) and glucose, z'3 There is 
uptake of amino acids, however, mainly glutamate. 4 
Glutamate has been shown to be important for the 
recovery of cardiac oxidative metabolism after isch- 
emia. s Because myocardial uptake of glutamate may 
be limited by substrate availability (arterial levels) 
during the first hours of reperfusion, 4 it has been 
suggested that metabolic recovery could be enhanced 
by the administration of exogenous glutamate. 1 
The aim of this study was to determine whether 
intravenous glutamate infusion increases myocardial 
uptake of glutamate and enhances the metabolic 
and functional recovery of the heart early after 
coronary artery bypass grafting (CABG) operations. 
Patients and methods 
Patients. Twenty male patients with stable angina pec- 
toris and well-preserved left ventricular function who were 
admitted for elective CABG operations were included in 
the study. None of the patients had either diabetes 
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Table I. Patient data 
Glutamate Control 
group group 
No. 10 10 
Age (yr) 62 _+ 2 62 _+ 1 
Weight (kg) 76 _+ 4 80 -+ 3 
BSA (m 2) 1.92 _+ 0.05 1.99 _+ 0.04 
No. of distal anastomoses 2.6 _+ 0.2 2.9 _+ 0.3 
Aortic crossclamp time (min) 34 _+ 5 32 -- 4 
CPB time (rain) 82 _+ 8 70 ± 7 
AST day 1 (/xkat/L) 1.72 + 0.17 1.41 ± 0.18 
Patient data are mean -+ SEM. There were no statistically significant 
differences between the groups. CPB, Cardiopulmonary bypass; AST, 
aspartate aminotransferase. 
mellitus or any other major metabolic disorder. Demo- 
graphic data are presented in Table I. 
Clinical management. After an overnight fast, the pa- 
tients were given intramuscularly 10mg morphine hydro- 
chloride and 0.4 mg scopolamine. Anesthesia was induced 
with thiopentone at a dose of 1 to 2 mg/kg body weight 
and fentanyl at a dose of 10/xg/kg body weight. Pancuro- 
nium bromide was used for neuromuscular blockade. 
Anesthesia was maintained with fentanyl and isoflurane. 
Cardiopulmonary bypass was conducted with a mem- 
brane oxygenator and a roller pump generating nonpul- 
satile flow. A crystalloid fluid containing no glucose or 
lactate (acetate Ringer's solution) and containing manni- 
tol was used to prime the extracorporeal circuit. Moderate 
hemodilution (hematocrit approximately 25%) and mod- 
erate hypothermia (30 ° to 32 ° C) were employed. Ante- 
grade delivery of St. Thomas' cold crystalloid cardioplegic 
solution was used for myocardial protection. Weaning 
from bypass was started when the patient was at a rectal 
temperature of 36 ° C. Heparin was neutralized with pro- 
tamine chloride. 
After operation and during the study period, the pa- 
tients were ventilated normally. Analgesia and sedation 
were achieved by a 10 to 15 ml/hour continuous infusion 
of alfentanil (0.46 mg/ml) and midazolam (0.4 mg/ml). 
Vecuronium bromide was given intermittently to prevent 
shivering. Postoperative r warming was facilitated by ra- 
diant heat provided by a thermal ceiling. Acetates Ring- 
er's solution was used for volume substitution to maintain 
atrial filling pressures at a constant level. None of the 
patients received blood or blood products either during 
the study period or later in the postoperative course. 
According to clinical routines, nitroglycerine, with ni- 
troprusside if necessary, was used to prevent postopera- 
tive hypertension to a pressure greater than 150 mm Hg. 
In the glutamate group, six patients received vasodilating 
agents before glutamate infusion and at the end of 
glutamate infusion. In the control group, three patients 
received vasodilating agents before the infusion and two 
patients required vasodilators at the end of the saline 
solution infusion. The dosages employed were low (nitro- 
1 1 prusside dose range 0.16 to 0.83 /xg. kg- • rain- ), and 
there were no significant changes during the study period 
in the requirements for nitroglycerine or nitroprussid e in 
either group. 
Table I I .  Composition of the 0.1 mol/L L-glutamic 
acid solution employed in the study 
Component Amount 
Glutamic acid (gin) 14.7 
Sodium chloride (gin) 3.0 
pH (adjusted with sodium hydroxide) 6.0 
Osmolality (mOsm/kg) 280 
Water was added to produce 1L solution. 
Study protocol. The study period commenced approx- 
imately 1 to 2 hours after completion of the operation. 
Ten patients received an infusion of 220 to 240 ml 0.1 
mol/L L-glutamic acid during 1 hour (glutamate group). 
The composition of this solution, which was prepared in 
the hospital pharmacy, is shown in Table II. To achieve 
variation in arterial glutamate l vels, the infusion rate was 
changed between the first and second 30-minute periods. 
The infusion rates for individual patients are listed in 
Table III. The 10 patients in the control group were given 
an infusion of 240 ml isotonic saline solution during 1 
hour. 
Blood samples were taken from the coronary sinus and 
radial artery immediately before the start of the L-glu- 
tamic acid or saline solution infusion (0 minutes, basal 
state), every 10 minutes during the infusion period, and 
also at 90 minutes for analysis of glucose, lactate, gluta- 
mate, alanine, and oxygen. In the basal state, at 30 
minutes, at 60 minutes, and at 90 minutes, samples were 
taken in duplicate. Blood samples analysis were taken for 
FFAs in the basal state, at 60 minutes, and at 90 minutes. 
Hemodynamic measurements were performed at 0, 30, 60, 
90, and 150 minutes. 
Catheterization procedure and hemodynamic measure- 
ments. The right atrium, left atrium, pulmonary artery, 
radial artery, and coronary sinus were catheterized for 
hemodynamic monitoring and blood sampling. The final 
midcoronary position of the coronary sinus catheter (Wil- 
ton Webster Labs Inc., Altadena, Calif.) was checked by 
fluoroscopy and measurement of oxygen saturation. Cor- 
onary sinus blood flow (CF 300A flowmeter; Webster 
Labs Inc.) and cardiac output were determined by ther- 
modilution technique; the mean values were calculated 
from three measurements. 6 
Biochemical analyses. Samples were obtained from the 
radial artery and the coronary sinus and analyzed in whole 
blood for glucose, lactate, glutamate, and alanine. Sam- 
ples were analyzed in plasma for FFAs. Whole blood was 
immediately deproteinized with ice-cold perchloric acid, 
as described by Jorfeldt and Juhlin-Dannfelt. 7 After cen- 
trifugation, the plasma and the protein-free extracts were 
deep-frozen to -70 ° C. Analysis was done by batches, with 
care being taken to ensure that corresponding arterial and 
venous samples were analyzed simultaneously. Glutamate 
concentration was determined fluorometrically by an 
adapted glutamate dehydrogenase method, s 
The D-glucose concentration was analyzed through a 
modification for fluorometry of the hexokinase method 
described by Schmidt, 9 Barthelmai, and Czok. 1° Lactate 
and alanine concentrations were also determined fluoro- 
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Fig. 1. Change in hemodynamic state from basal state to 
60 minutes, expressed as percentages (mean + SEM) in 
control (hatched bars) and glutamate (gray bars) groups. 
CI, Cardiac index; HR, heart rate; MAP, mean arterial 
pressure; SVR/, systemic vascular resistance index; 
LVSWI, left ventricular stroke work index. Asterisks indi- 
cate statistically significant differences from basal state, 
with single asterisk representing p < 0.05 and double 
asterisk representing p < 0.01. 
metrically. 11 FFAs were analyzed according to the method 
of Ho.  12 
Oxygen saturation and hemoglobin concentrations were 
measured with an OSM3 oximeter (Radiometer AS, 
Copenhagen, Denmark). 
Calculations and efinitions. Oxygen consumption of 
the heart was estimated as the product of the arterial- 
coronary sinus blood oxygen content difference and the 
coronary sinus blood flow. Oxygen content of the blood 
(in millimoles per liter) was calculated according to the 
following formula: Oxygen content = [B-Hb • So2" (6.2 × 
10-4)] + (P%. 0.01), where B-Hb represents blood level 
of hemoglobin (in grams per liter); So2 is oxygen satura- 
tion expressed as a percentage; and Po2 is oxygen tension 
(in kilopascals). 
Myocardial fluxes of glutamate, glucose, lactate, and 
alanine were calculated as the product of arterial-coro- 
nary sinus blood concentration differences with coronary 
sinus blood flow. 
Myocardial flux of FFAs was calculated as the product 
of arterial-coronary, sinus plasma concentration differ- 
ence with coronary sinus plasma flow. A release of 
substrates was defined as a flux value significantly ess than 
zero (p < 0.05). An uptake of substrates was defined as a 
flux value significantly greater than zero (/9 < 0.05). The 
term basal state refers to measurements performed imme- 
diately before the start of glutamate or saline solution 
infusion. Hemodynamic parameters were calculated from 
standard formulas. 
Statistical methods. Statistical analyses were per- 
formed with a computerized statistical package (RS/1; 
Bolt Beranek and Newman Inc., Cambridge, Mass.). The 
normal distribution of the samples was analyzed by the 
Wilk-Shapiro test, and the t test was used as appropriate 
for paired and unpaired comparisons. For samples lacking 
normal distribution, the statistical package automatically 
converted to nonparametric tests: the Wilcoxon test for 
Table III. Varying infusion rates of glutamate in 
individual patients during first and second 30-minute 
periods 
Patient No. 0-30 min 30-60 rain 
1 40.4 47.8 
2 39.2 58.8 
3 36.0 60 
4 36.2 67.8 
5 30.9 66.3 
6 26.5 72.5 
7 18.1 68.9 
8 9.8 57.4 
9 31.1 68.3 
10 12.4 87.0 
Rates are mg " kg -I  body weight • hr 2. 
matched pairs and the Mann-Whitney U-test for unpaired 
observations. Statistical significance was defined as a p 
value less than 0.05. Data are presented as means (_+ 
standard error of the mean [SEM]). 
Ethical aspects. The study was performed according to 
the principles of the Helsinki Declaration of Human 
Rights and was approved by the ethics committee for 
medical research at the University Hospital of Link6ping. 
Informed consent was obtained from each patient. 
Results 
Clinical course. The postoperative course was 
uneventful in both groups, and no side effects of 
either infusion were seen. None of the patients 
required inotropic support and none had electrocar- 
diographic or enzymatic signs of  perioperative myo- 
cardial infarction (Table I). 
Hemodynamic parameters. Detailed hemody- 
namic results are given in Table IV. The changes in 
hemodynamic state from the basal state to 60 min- 
utes are demonstrated in Fig. 1. 
Glutamate group. Left ventricular stroke work 
index increased from 26.8 _+ 2.1 gin.  beats -1 • m -2 
body surface area (BSA; basal state) to 31.3 _+ 3.1 
gin.  beats -1 .  m -2 BSA after 60 minutes of gluta- 
mate infusion. Cardiac index increased during the 
same period from 2.0 _+ 0.1 L .  rain -1-  m -2 BSA 
(basal state) to 2.3 _+ 0.1 L - ra in  -1 .m -2 BSA. 
There were also increases in mean arterial pressure 
and heart rate during glutamate infusion. There was 
no further improvement in the next 90 minutes. The 
left atrial filling pressure did not change significantly 
during glutamate infusion, but there was an increase 
in central venous pressure from 6.0 _+ 0.7 mm Hg 
(basal state) to 6.5 _+ 0.8 mm Hg (60 minutes). 
Cardiac index was significantly higher in the glu- 
tamate group than in the control group at 60 
minutes. Mean arterial pressure was significantly 
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Cardiovascular Surgery 
Volume 112, Number 6 
Svedjeholm et al. 1 4 7 1 
Table IV. Hemodynamic results and myocardial oxygen consumption 
0 min 30 min 60 rain 90 rain 150 rain 
CI 
Glutamate 2.0 _+ 0.1 2.2 _+ 0.1" 2.3 ± OAt:) 2.3 _+ 0.2* 2.4 +_ 0.2* 
Control 2.0 _+ 0.1 2.0 _+ 0.1 2.0 _+ 0.1 2.1 ± 0.1 2.1 ± 0.1 
HR 
Glutamate 77 ± 3 80 ± 4? 83 + 4? 84 + 3? 89 ± 4? 
Control 75 _+ 5 75 ± 5 76 ± 5 76 ± 5 81 _+ 5 
SVI 
Glutamate 26.7 ± 1.8 27.6 _+ 1.8 28.2 _+ 1.8 27.0 _+ 1.7 27.1 ± 1.8 
Control 27.9 _+ 2.0 28.3 _+ 2.3 27.8 _+ 2.3 28.4 _+ 2.5 26.7 +_ 2.3 
MAP 
Glutamate 81 ± 3 88 -+ 4":~ 88 -+ 4* 84 _+ 3* 90 _+ 5* 
Control 81 -- 3 79 ± 2 81 ± 2 81 _+ 3 81 ± 2 
SVRI 
Glutamate 3026 ± 193 3051 _+ 150 2844 ± 119 2784 _+ 110" 2795 _+ 106" 
Control 2997 4- 180 2855 _+ 152 2941 +_ 192 2877 _+ 184 2942 _+ 175 
PVRI 
Glutamate 352 _+ 22 333 _+ 23 332 ± 25 360 ± 34 365 ± 32 
Control 326 ± 25 342 ± 45 367 -+ 41 359 +_ 39 388 _+ 38 
LVSWI 
Glutamate 26.8 _+ 2.1 30.4 _+ 3.2* 31.3 _+ 3.1' 26.8 -- 2.9 31.0 ± 4.2 
Control 29.4 ± 1.7 30.0 -+ 3.0 30.1 _+ 2.7 30.5 _+ 2.8 29.2 _+ 3.5 
LAP 
Glutamate 6.9 _+ 0.8 7.2 ± 1.0 7.2 ± 1.0 7.3 4- 0.9* 7.2 4- 0.8 
Control 8.4 _+ 0.5 8.8 _+ 0.5 8.8 +_ 0.5 8.3 ± 0.6 8.0 ± 0.5 
CVP 
Glutamate 6.0 ± 0.7:~ 6.3 _+ 0.7.~ 6.5 _+ 0.87~: 7.2 +_ 0.6?:) 7.2 + 0.8 
Control 7.6 _+ 0.5 8.0 ± 0.6 8.0 4- 0.3 8.0 ± 0.4 7.2 + 0.5 
Svo z 
Glutamate 72 ± 2 73 _+ 2 72 +_ 2 71 _+ 2 69 _+ 2* 
Control 72 _+ 1 72 _+ 2 73 -- 1 72 ± 2 70 ± 2 
CSF 
Glutamate 136 4- 19 142 -- 16 151 + 24 115 ± 21 136 ± 32 
Control 143 ± 21 154 + 26 148 ± 21 135 _+ 16 § 
CSSo 2 
Glutamate 45 ± 1:) 43 _+ 1~ 42 ± 1" 42 ± 1:~ 42 ± 2 
Control 48 _+ 2 48 ± 2 45 +_ 2? 46 ± 2? § 
MVo 2 
Glutamate 529 _+ 66 557 +_ 58 603 ± 100 447 ± 72 555 ± 134 
Control 551 ± 100 601 _+ 114 597 _+ 92 552 ± 78 § 
Data are mean -+ SEM for basal state (0 min) and at 30, 60, 90, and 150 minutes. C/, Cardiac index (L- min -1 • m -2 BSA); FIR, heart rate (beats/min); SV/;, 
stroke volume index (ml" beats 1. m 2 BSA); MAP, mean arterial pressure (mm Hg); SVR/, systemic vascular esistance index (dynesec. m 5. m 2 BSA); 
PVRI, pulmonaryvascularresistanceindex(dynesec'cm-5"m-2BSA);LVSWI, leftventricular st oke work index (gm . beats a-m 2BSA);LAP, left atrial 
pressure (ram Hg); CVP, central venous pressure (mm Hg); Sv02, mixed venous oxygen saturation (%); CSF, coronary sinus blood flow (ml/min); CSSos, 
coronary sinus blood oxygen saturation (%); MVoa, myocardial oxygen consumption (txmol/min). 
• Statistically significant differences compared with basal state, p < 0.05. 
?Statistically significant differences compared with basal state, p < 0.01. 
~Statistically significant differences between glutamate group and control group, p < 0.05. 
§No sampling at 150 minutes. 
higher in the glutamate group than in the control 
group at 30 minutes. Atrial filling pressures tended 
to be slightly lower in the glutamate group during 
the study period than in the control group (statisti- 
cally significant for central venous pressure). There 
were no significant changes in myocardial oxygen 
uptake or coronary sinus blood flow during the study 
period. 
Control group. In the control group, there were 
no significant hemodynamic changes during the 
study period. There were also no significant changes 
in myocardial oxygen uptake or coronary sinus 
blood flow. 
Biochemical parameters. Detailed results of ar- 
terial levels of substrates and myocardial flux are 
given in Tables V and VI and Figs. 2 through 4. 
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Table V. Arterial levels of substrates 
Time (rain) Glutamate (ixmol/L) Alanine (p.moI/L) Lactate (mmol/L) Glucose (mmol/L) FFAs (mmol/L) 
0 
Glutamate 103 _+ 10" 273 _+ 21 1.05 ± 0.15 6.0 + 0.17 1.17 _+ 0.04* 
Control 162 _+ 7 287 _+ 21 1.03 -- 0.12 5.4 _+ 0.3 0.62 + 0.06 
10 
Glutamate 172 _+ 14:) 280 -- 22 1.02 -+ 0.155 6.0 ± OAt 
Control 161 +_ 9 259 _+ 245 1.00 -+ 0.11 5.3 ± 0.3~+ 
20 
Glutamate 186 _+ 185 273 _+ 23 0.99 -+ 0.14 6.0 ± 0.1§ 
Control 157 _+ 8 283 _+ 20 1.00 _+ 0.11 5.2 ± 0.2ll 
30 
Glutamate 189 ± 195 276 _+ 23 0.97 ± 0.1411 5.9 ± 0.1§ 
Control 157 _+ 8 271 _+ 145 0.94 -+ 0.09 5.2 _+ 0.3¶ 
6O 
Glutamate 394 + 20*$ 277 + 27 0.97 ± 0.14 5.9 ± 0.1§ 1.08 ± 0.06? 
Control 160 +_ 7 283 _+ 13 0.90 ± 0.07 5.1 _+ 0.25 0.84 _+ 0.095 
90 
Glutamate 129 _+ 17% 275 _+ 27 0.96 ± 0.13 5.9 + 0.1" 0.98 _+ 0.075** 
Control 157 _+ 8 256 ± lgll 0.83 -- o.o611 5.0 ± 0.3¶ 0.87 _+ 0.09:) 
Data are mean _+ SEM for the basal state (0 min) and at 10, 20, 30, 60, and 90 minutes. 
*Statistically significant differences between glutamate group and control group, p < 0.001. 
?Statistically significant differences between glutamate group and control group, p < 0.05. 
:I:Statistically significant differences compared with basal state, p < 0.01. 
{}Statistically significant differences between glutamate group and control group, p < 0.01. 
]]Statistically significant differences compared with basal state, p < 0.05. 
¶Statistically significant differences compared with basal state, p < 0.001. 
**Samples taken at I50 minutes. 
Average myocardial uptakes of glutamate and cor- 
responding arterial levels of glutamate during the 
study period are depicted in Fig. 2. The changes in 
myocardial flux of substrates during the study period 
are depicted in Fig. 3. 
Glutamate 
GLUTAMATE GROUP. During glutamate infusion, a 
significant increase in the myocardial uptake of 
glutamate was observed, with an early peak of 5.7 _+ 
1.2 /xmol/min at 20 minutes. Arterial glutamate 
levels increased from 103 _+ 10/xmol/L (basal state) 
to 394 _+ 20/xmol/L at 60 minutes. During the first 
30-minute period, there was a significant correlation 
between arterial levels (r = 0.61, p < 0.001) and 
arterial-coronary sinus differences. Thirty minutes 
after discontinuation of glutamate infusion, arterial 
levels had decreased to 129 _+ 17/zmol/L. 
CONTROL GROUP. In the basal state, the arterial 
level of glutamate and the myocardial uptake of 
glutamate were significantly higher in the control 
group than in the glutamate group. There were no 
changes in uptake in the control group during the 
study period. 
Alanine 
GLUTAMATE GROUP. In the basal state, there was a 
significant myocardial release of alanine in the glu- 
tamate group. A significant decrease in alanine 
release was observed at 30 minutes. Arterial levels 
of alanine remained unchanged uring the study 
period. 
CONTROL GROUP. In the basal state, there was a 
significant release of alanine in the control group. A 
significant decrease in alanine release was observed 
at 20 minutes. Arterial levels of alanine in the 
control group decreased uring the study period 
'statistically significant at 10, 30, and 90 minutes). 
Lactate 
GLUTAMATE GROUP. Myocardial uptake of lactate 
increased from 4.9 _+ 2.0/xmol/min (basal state) to 
14.1 --- 4.4/xmol/min after 60 minutes of glutamate 
infusion. Arterial levels of lactate decreased (statis- 
tically significant at 10 and 30 minutes), and the 
fractional uptake of lactate increased from 3.5% _+ 
1.2% (basal state) to 8.7% _+ 2.2% at 60 minutes 
(Fig. 4). 
CoYrROL GROUP. In the basal state, myocardial 
uptake of lactate was significantly higher in the 
control group than in the glutamate group. In 
contrast o the glutamate group, myocardial uptake 
decreased significantly during the study period. Ar- 
terial levels decreased uring the study period (sta- 
tistically significant at 90 minutes). 
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Table VI. Myocardial flux of substrates (t.tmol/min) 
Time (rain) Glutamate Alanine Lactate Glucose FFA 
0 
Glutamate 0.7 _+ 0.2*? -3.2 +_ 0.85 4.9 + 2.0*§ 17.8 +_ 6.3* 17.1 -+ 2.251[ 
Control 4.7 _+ 1.3¶ -3.5 -+ 1.15 18.9 -- 5.45 10.2 _+ 4.8* 9.6 -- 2.55 
10 
Glutamate. 3.1 + 0.55** -2.0 _+ 1.0' 4.2 _+ 1.4511 13.5 -+ 9.4 
Control 5.1 _+ 1.8¶ -6.2 _+ 2.3* 16.6 _+ 5.6:~ 7.9 _+ 12.4 
20 
Glutamate 5.7 _+ 1.25"* -2.0 _+ 0.8* 6.3 _+ 3.61[ 14.0 _+ 9.7 
Control 5.4 _+ 1.95 -0.8 +- 2.8?? 19.0 _+ 6.35 11.8 _+ 17.1 
30 
Glutamate 4.2 _+ 1.05"* -2.0 _+ 1.1"?? 5.2 _+ 2.7* 5.0 -+ 12.7 
Control 4.2 +_ 1.65 -4.4 _+ 1.65 12.6 _+ 4.1577 5.4 -+ 11.1 
60 
Glutamate 4.4 -+ 1.0" ** -2.8 _+ 1.1" 14.1 + 4.45?? 13.7 _+ 13.2 16.7 _+ 3.85 
Control 3.6 +_ 1.05 -3.4 +_ 1.2:~ 10.8 _+ 3.75?? 7.3 -+ 3.7* 14.4 _+ 5.05 
90 
Glutamate 1.8 -+ 0.45** -3.1 _+ 0.65 10.2 _+ 3.45?? 11.1 _+ 5.9* 20.0 _+ 8.75 55 
Control 3.2 _+ 0.8¶ -4.9 _+ 1.2:) 5.2 _+ 2.8*?? -1.0 -+ 6.4 14.2 _+ 2.85 
Data are mean -+ SEM for basal state (0 min) and at 10, 20, 30, 60, and 90 minutes. 
*Statistically significant uptake or release, p < 0.05. 
?Statistically significant differences between glutamate group and control group, p < 0.001. 
:~Statistieally significant uptake or release, p < 0.01. 
§Statistically significant differences between glutamate group and control group, p < 0.01. 
I[Statistically significant differences between glutamate group and control group, p < 0.05. 
¶Statistically significant uptake or release, p < 0.001. 
**Indicate statistically significant differences compared with basal state, p < 0.01. 
"PHndicate statistically significant differences compared with basal state, p < 0.05. 
:~$Samples taken at 150 minutes. 
Glucose 
GLUTAMATE GROUP. In the basal state, there was a 
significant myocardial uptake of glucose (17.8 + 6.3 
/zmol/min). There was no significant change in up- 
take during the study period. Arterial levels re- 
mained unchanged. 
CONTROL GROUP. In the basal state, there was a 
significant myocardial uptake of glucose (10.2 + 4.8 
/xmol/min). There was no significant change in up- 
take during study period. Arterial glucose levels in 
the basal state were significantly ower in the control 
group than in the glutamate group, and there was a 
decrease in arterial glucose levels during the study 
period. 
FFAs 
GLUTAMATE GROUP. A significant myocardial up- 
take of FFAs (17.1 + 2.2/,mol/min) was observed in 
the basal state in the glutamate group. There was no 
significant change during the study period. The 
arterial evel of FFAs decreased from 1.17 _+ 0.04 
mmol/L (basal state) to 1.08 _+ 0.06 mmol/L at 60 
minutes (p = 0.052) and to 0.98 _+ 0.07 at 150 
minutes (p < 0.01). 
CONTROL GROUP. A significant myocardial uptake 
of FFAs (9.6 _+ 2.5/xmol/min) was observed in the 
basal state in the control group. There was no 
significant change during the study period. The 
arterial evel of FFAs increased from 0.62 +_ 0.06 
mmol/L (basal state) to 0.84 _+ 0.09 mmol/L at 60 
minutes and 0.87 _+ 0.09 at 90 minutes. Despite this 
increase, the arterial level was significantly ower in 
the control group than in the glutamate group in the 
basal state and at 60 minutes. 
Discussion 
The main finding of this study is that glutamate 
infusion early after coronary operations was associ- 
ated with increased myocardial uptake of glutamate 
and improved myocardial extraction of lactate. The 
results are compatible with an improvement in 
myocardial oxidative metabolism and were associ- 
ated with improved myocardial performance. Intra- 
venous metabolic support with glutamate may there- 
fore provide a means of improving metabolic and 
functional recovery of the heart after coronary 
operations. 
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Fig. 2. Myocardial glutamate uptake (/xmol/min; bars) 
and arterial glutamate lev l (p~mol/L; straight line with 
squares) according to whole blood analyses (mean _+ 
SEM). Asterisks indicate statistically significant differences 
from basal state, with single asterisk representingp < 0.05 
and double asterisk representingp < 0.01. 
Some aspects of study design deserve to be con- 
sidered. The study was neither blind nor random- 
ized because data on the impact of glutamate ad- 
ministration on arterial levels, myocardial g utamate 
uptake, and adverse ffects were limited when the 
study was planned. The descriptive nature of the 
study was therefore mphasized. More important, 
early detection of any signs suggestive of adverse 
effects was considered mandatory. The main pur- 
pose of the control group was to provide informa- 
tion about metabolic and hemodynamic changes 
occurring spontaneously during the study period. 
Although the inclusion criteria were strict, some 
minor differences between the glutamate and con- 
trol groups were observed. Obviously, randomiza- 
tion might have avoided these differences. Despite 
these limitations, we suggest that the results are 
relevant. They agree with basic science data and 
available data from human studies and therefore 
may serve as encouragement forfuture randomized 
studies and provide approximate guidelines with 
respect to the choice of dosages for these studies. 
Impaired myocardial utilization of oxygen has 
been demonstrated arly after ischemia, s' 13, 14 In 
animals, amino acids, particularly glutamate and 
aspartate, are important in the recovery of myocar- 
dial oxidative metabolism after ischemia. 5' t5 These 
observations also seem relevant for human beings, 
according to studies performed in association with 
cardiac operations. 2, 4 Moreover, a high fractional 
uptake of glutamate has been demonstrated arly 
after coronary operations, indicating that substrate 
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Fig. 3. Change in myocardial flux of substrates in control 
(hatched bars) and glutamate (gray bars) groups from the 
basal state to 60minutes (mean _+ SEM). Glut, Gluta- 
mate; Lact, lactate; Ala, alanine; Gluc, glucose; FFA, free 
fatty acids. Asterisks indicate statistically significant differ- 
ences from basal state, with single asterisk representing 
p < 0.05. 
availability may be limiting for the uptake of gluta- 
mate during the first hours of reperfusion. 4 It has 
therefore been suggested that exogenous adminis- 
tration of glutamate could enhance metabolic and 
possibly functional recovery of the heart. 1
In this study, a significant increase in the myocar- 
dial uptake of glutamate was observed uring glu- 
tamate infusion, with an early peak at 20 minutes. 
Although myocardial uptake of glutamate corre- 
lated with the arterial level during the first half hour, 
an increase in arterial (whole blood) levels more 
than twofold or threefold was not associated with a 
further increment in myocardial glutamate uptake. 
The results suggest that myocardial glutamate up- 
take is dependent not only on arterial evels but 
probably also on myocardial requirements. Data 
obtained at peak uptake of glutamate (unpublished 
data) suggest hat an infusion rate of 30 to 40 
rag-kg -1. hour 1 may be sufficient o adequately 
enhance myocardial glutamate uptake, at least after 
routine CABG operations. The precise mechanisms 
governing myocardial glutamate uptake in the heart 
are not known at present. The roles of carrier 
proteins and different ransport systems for amino 
acids in various tissues has received increasing at- 
tention during the last decade. Recently published 
data point out the pH dependence of L-glutamate 
transport in sarcolemmal vesicles from rat heart. 16 
Acidosis in ischemic heart regions may therefore 
explain the increased uptake of glutamate in isch- 
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emic and postischemic hearts. A high turnover of 
glutamate in the human body is suggested by the 
rapid decrease of arterial levels after discontinua- 
tion of glutamate infusion. 
The arterial FFA level was reduced during the 
study period in the glutamate group, whereas arte- 
rial level increased in the control group. Reduction 
of arterial FFA levels is considered esirable for the 
postischemic heart~7; however, the change in this 
study was small. Reduced FFA levels have been 
reported previously during glutamate administra- 
tion as a result of increased insulin secretion. Is In 
normal subjects, maximal reduction of plasma FFA 
levels may appear at plasma insulin levels as low as 
30 mU/L, which correspond to the reported incre- 
ment in insulin during glutamate infusion. 17' ~8 After 
CABG operations, however, only a minor impact on 
arterial FFA levels has been reported at these 
insulin levels, and no effect on myocardial uptake of 
substrates may be expected. 17' 19 In agreement with 
this, there was no change in the net uptake of the 
major substrates (FFAs and glucose) during gluta- 
mate infusion. 
The myocardial uptake of lactate, however, in- 
creased almost hreefold uring glutamate infusion. 
Lactate uptake is normally dependent on arterial 
levels. 2° The increase in lactate uptake was not the 
result of increased arterial evels, however; on the 
contrary, the arterial levels of lactate decreased 
somewhat, whereas the fractional uptake of lactate 
increased significantly from 3.5% to 8.7% during 
glutamate infusion (Fig. 4). These results are com- 
patible with an improved myocardial utilization of 
lactate. The methods used in this study do not allow 
a precise assessment of the metabolic fate of lactate; 
in the human heart, however, the metabolic path- 
ways after conversion of lactate to pyruvate are 
limited to either (1) transamination to alanine, (2) 
oxidation in the Krebs cycle after oxidative decar- 
boxylation by pyruvate dehydrogenase, and possibly 
(3) pyruvate carboxylation to form oxaloacetate, 
thereby regenerating Krebs cycle intermediates. 21 
Because alanine release tended to decrease in this 
study, an increased transamination of pyruvate is 
unlikely. We therefore suggest that glutamate infu- 
sion was associated with an improved oxidation of 
lactate. These findings agree with animal experi- 
mental data, which demonstrate improved recovery 
of myocardial oxidative metabolism after ischemia 
by substrate nhancement with glutamate. 5 
It may be argued that the net myocardial uptake 
of lactate observed in the basal state is incompatible 
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Fig. 4. Fractional (%) uptake of lactate in glutamate 
group (mean + SEM). Asterisks indicate statistically sig- 
nificant differences from basal state, with single asterisk 
representingp < 0.05 and double asterisk representingp < 
0.01. 
with defective oxidative metabolism. The myocar- 
dial protection provided by antegrade crystalloid 
cardioplegia, however, may vary considerably in 
different regions of the heart. This implies that 
disturbances of oxidative metabolism ay also vary 
considerably regionally. The coronary-sinus catheter 
technique, however, reflects global left ventricular 
metabolism. 6 Low levels of lactate extraction in the 
early reperfusion period thus may represent the net 
result of continued lactate release from poorly pro- 
tected regions and lactate utilization in well-pro- 
tected regions. The improved lactate utilization 
during glutamate infusion may be the result of 
regionally improved oxidative metabolism in poorly 
protected parts of the heart. 22 Analogously, the 
increase in global myocardial oxygen consumption 
observed uring glutamate infusion, although not 
statistically significant, may be compatible with re- 
gionally improved oxidative metabolism. 
The major hemodynamic effects of glutamate 
infusion were increases in left ventricular stroke 
work and mean arterial blood pressure, compatible 
with improved myocardial performance. The impact 
of intravenous glutamate on myocardial metabolism 
and myocardial performance agree with data from 
animal experiments in which L-glutamate was used 
as a cardioplegic additive, s In contrast o clinical 
experience with amino acid- enhanced blood cardio- 
plegia (unpublished ata), we did not observe any 
signs of vasodilation. To explain this discrepancy, 
the higher arterial levels of glutamate (and aspar- 
tate) after amino acid-enhanced blood cardiople- 
gia, 23 other components of the cardioplegic solution 
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and conditions caused by cardiopulmonary b pass 
must be considered. Because the increase in cardiac 
index was not primarily an effect of vasodilation, it is 
also evident hat the limited employment of vasodi- 
lators to prevent postoperative hypertension has 
minor impact on the hemodynamic results. The 
positive hemodynamic mpact of glutamate in this 
study provides further support for the suggested link 
between metabolic and hemodynamic func- 
tion.i, 24, 25 
In human beings, positive metabolic and hemody- 
namic effects of glutamate were demonstrated by 
Pisarenko, Lepilin, and Ivanov 26 in patients treated 
with dopamine because of heart failure after cardiac 
operations. These patients differed from those in 
our study by their poorer hemodynamic condition, a
more severe degree of metabolic derangement, and 
more pronounced metabolic and hemodynamic re- 
sponses to glutamate. The metabolic and hemody- 
namic impact of glutamate may therefore be related 
to the magnitude of metabolic derangement before 
treatment. 
Timing of intervention and patient selection are 
factors that could influence the impact of metabolic 
treatment. This study was started 1 to 2 hours after 
completion of the operation because previous tud- 
ies performed uring this period demonstrated myo- 
cardial metabolic abnormalities that seemed acces- 
sible to glutamate treatment. 4 The patients in the 
glutamate group, however, demonstrated myocar- 
dial metabolic alterations that were minor com- 
pared with these studies. This discrepancy is proba- 
bly explained by the shorter aortic crossclamp times, 
the lesser extent of coronary artery disease, and the 
employment of a superior degree of sedation and 
muscle relaxation in this study. Metabolic derange- 
ment was even less pronounced in the control group, 
and it is uncertain whether these patients would 
have benefited from glutamate administration at 
this stage. Further studies hould focus on glutamate 
administration during early reperfusion in patients 
undergoing more extensive operations, patients at 
high risk, and patients with postoperative heart 
failure. 
Our results suggest that patients undergoing rou- 
tine CABG with short aortic crossclamp times may 
still benefit from glutamate, however, so the role of 
glutamate administration as a clinical routine also 
deserves further investigation. In this respect, intra- 
venous glutamate administration offers an alterna- 
tive to amino acid enhancement of cardioplegic 
solutions. It is unlikely, however, that additional 
intravenous amino acid administration would pro- 
vide further benefit during early reperfusion in 
patients receiving amino acid-enhanced cardiople- 
gia. On the other hand, preoperative and postoper- 
ative ischemia may now be more important deter- 
minants of clinical outcome in coronary operations 
as a result of current standards of myocardial pro- 
tection.27, 28 Because glutamate is reported to im- 
prove myocardial tolerance to ischemia in patients 
with coronary problems, 29 intravenous glutamate 
administration offers the prospect of improving 
myocardial protection during the preoperative and 
postoperative periods of CABG. These and other 
issues discussed here should be addressed in pro- 
spective, randomized studies. 
This study suggests that intravenous glutamate 
infusion can enhance myocardial uptake of gluta- 
mate and improve metabolic and hemodynamic 
recovery of the heart early after coronary opera- 
tions. Randomized studies are needed to confirm 
these results and to explore the therapeutic and 
prophylactic potentials of the intravenous adminis- 
tration of amino acids. 
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